Zurcher Kantonalbank Zurich Cantonalbank Has $3.93 Million Stock Holdings in Laboratory Co. of America Holdings (NYSE:LH)

Zurcher Kantonalbank Zurich Cantonalbank lowered its stake in shares of Laboratory Co. of America Holdings (NYSE:LH) by 3.2% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 17,119 shares of the medical research company’s stock after selling 570 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Laboratory Co. of America were worth $3,926,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of LH. Amundi lifted its holdings in shares of Laboratory Co. of America by 344.9% during the 4th quarter. Amundi now owns 1,123,409 shares of the medical research company’s stock valued at $263,161,000 after buying an additional 870,903 shares during the last quarter. Dorsey & Whitney Trust CO LLC lifted its stake in Laboratory Co. of America by 1.7% in the fourth quarter. Dorsey & Whitney Trust CO LLC now owns 3,296 shares of the medical research company’s stock valued at $756,000 after acquiring an additional 56 shares during the last quarter. PNC Financial Services Group Inc. grew its position in Laboratory Co. of America by 3.7% in the fourth quarter. PNC Financial Services Group Inc. now owns 40,346 shares of the medical research company’s stock worth $9,252,000 after acquiring an additional 1,431 shares in the last quarter. Welch & Forbes LLC grew its position in Laboratory Co. of America by 7.2% in the fourth quarter. Welch & Forbes LLC now owns 1,630 shares of the medical research company’s stock worth $374,000 after acquiring an additional 110 shares in the last quarter. Finally, E Fund Management Co. Ltd. increased its stake in shares of Laboratory Co. of America by 75.1% during the 4th quarter. E Fund Management Co. Ltd. now owns 1,644 shares of the medical research company’s stock worth $377,000 after purchasing an additional 705 shares during the last quarter. 95.94% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Laboratory Co. of America

In other Laboratory Co. of America news, Director Kerrii B. Anderson sold 500 shares of the stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $255.63, for a total transaction of $127,815.00. Following the completion of the transaction, the director now directly owns 13,166 shares in the company, valued at $3,365,624.58. This represents a 3.66 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Der Vaart Sandra D. Van sold 1,314 shares of the business’s stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $251.30, for a total transaction of $330,208.20. Following the completion of the sale, the executive vice president now owns 2,171 shares in the company, valued at $545,572.30. This represents a 37.70 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 14,500 shares of company stock valued at $3,577,572. Company insiders own 0.85% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on LH shares. Evercore ISI raised shares of Laboratory Co. of America from an “in-line” rating to an “outperform” rating and lifted their price objective for the company from $260.00 to $265.00 in a research note on Tuesday, January 7th. Bank of America boosted their price target on Laboratory Co. of America from $262.00 to $271.00 and gave the stock a “buy” rating in a research report on Friday, December 13th. Piper Sandler increased their price objective on Laboratory Co. of America from $240.00 to $260.00 and gave the company a “neutral” rating in a report on Monday, February 10th. Citigroup upgraded Laboratory Co. of America from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $250.00 to $300.00 in a report on Tuesday, March 4th. Finally, Barclays lowered their price target on Laboratory Co. of America from $271.00 to $260.00 and set an “equal weight” rating on the stock in a report on Friday, February 7th. Three analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Laboratory Co. of America presently has an average rating of “Moderate Buy” and an average price target of $268.38.

Laboratory Co. of America Stock Up 1.8 %

NYSE LH opened at $239.80 on Friday. Laboratory Co. of America Holdings has a twelve month low of $191.97 and a twelve month high of $258.59. The stock has a market cap of $20.07 billion, a PE ratio of 27.19, a PEG ratio of 1.71 and a beta of 1.12. The firm has a 50-day simple moving average of $244.69 and a 200 day simple moving average of $234.04. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.30 and a current ratio of 1.44.

Laboratory Co. of America (NYSE:LH) last announced its quarterly earnings data on Thursday, February 6th. The medical research company reported $3.45 EPS for the quarter, topping analysts’ consensus estimates of $3.40 by $0.05. Laboratory Co. of America had a return on equity of 15.29% and a net margin of 5.73%. On average, research analysts forecast that Laboratory Co. of America Holdings will post 16.01 EPS for the current year.

Laboratory Co. of America Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, March 12th. Stockholders of record on Thursday, February 27th were paid a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.20%. The ex-dividend date of this dividend was Thursday, February 27th. Laboratory Co. of America’s dividend payout ratio is 32.65%.

Laboratory Co. of America Profile

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.